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Abstract
The epithelia that line the conducting airways are the lung’s first point of contact with inhaled
pathogens and toxicants. As such, they are known to play an important role in the lung’s innate
defense system, which includes (i) the production of airway surface liquid (ASL) that helps
cleanse the airways through the physical removal of pathogens and toxicants on the mucociliary
escalator and (ii) the secretion of anti-microbial proteins into the ASL to kill inhaled pathogens.
Interestingly, the recently crystallized short palate lung and nasal epithelial clone 1 (SPLUNC1)
protein appears to be a multi-functional protein. That is, it not only acts as an anti-microbial agent,
but also modulates ASL homeostasis by acting as an endogenous inhibitor of the epithelial Na+
channel (ENaC). This review will focus on the latter function of SPLUNC1, and will discuss new
structural and physiological data regarding SPLUNC1’s failure to function as a regulator of ASL
hydration in CF airways.
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1. Introduction
Human, short palate lung and nasal epithelial clone 1 (SPLUNC1) is a 256 amino acid
secreted protein that is highly expressed in airway epithelia (Di, 2011). SPLUNC1
nomenclature has varied since it was first discovered. Originally it was termed PLUNC
(Weston et al., 1999), however, the “short” prefix was later added as it became part of a
family of long and short PLUNCs (Bingle and Craven, 2002). Subsequently, based its
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structural homology to bacterial permeability increasing protein (BPI), an archetypal anti-
microbial factor, it was also named BPIFA1 (BPI-family member A1). To further
complicate matters, SPLUNC1 has also been referred to as LUNg specific protein-X
(LUNX) (Iwao et al., 2001), nasopharyngeal carcinoma-related protein (NASG) (Zhang et
al., 2003) and secreted protein from upper respiratory tract (SPURT) (Di et al., 2003).
Regardless of name, SPLUNC1 is thought to play an important role in lung innate defense
through a number of different means. SPLUNC1 has been shown to have anti-bacterial
activity against Klebsiella pneumonia, Mycoplasma pneumoniae, Pseudomonas aeruginosa,
and Staphylococcus aureus (Gally et al., 2011), as well as anti-viral activity (Epstein–Barr
virus) (Zhou et al., 2008). Additionally, SPLUNC1 can regulate ion/mucus transport and
hydration levels in the lung (Gaillard et al., 2010), lower surface tension through its
surfactant-like properties (Bartlett et al., 2011), and act as an inflammatory mediator (Di,
2011). In general, there is little mechanistic data available regarding how SPLUNC1
performs these functions. But, in light of SPLUNC1’s recently determined crystal structure,
some insights have been gained. This review will focus on how these molecular details
relate to SPLUNC1’s ability to regulate ion transport in normal and cystic fibrosis (CF)
airways by acting as an endogenous inhibitor of the epithelial Na+ channel (ENaC).
2. The epithelial sodium channel (ENaC)
ENaC is a heterotrimer that consists of α, β, and γ subunits (Rossier and Stutts, 2008). Each
subunit contains intracellular N-and C-termini, two transmembrane spanning domains, and a
large extracellular loop. The extracellular loops of the α and γ ENaC subunits can be
proteolytically cleaved at multiple sites by many types of proteases including furin-type
convertases, trypsin-like serine proteases, neutrophil elastase, and acid proteases, leading to
activation of the channel and increased Na+ absorption (Rossier and Stutts, 2008; Hughey et
al., 2007; Alli et al., 2012). Both trypsin-like proteases (e.g., prostasin) and acid proteases
(e.g., cathepsin B) are secreted by airway epithelia into the ASL (Kesimer et al., 2009), so
there is a wide variety of proteases that can activate ENaC. Furthermore, during times of
inflammation, neutrophil-derived proteases such as neutrophil elastase are also secreted into
the ASL and may additionally cleave ENaC (Caldwell et al., 2005). Indeed, it has been
proposed that excessive protease activity seen in CF sputum contributes to abnormal
regulation of ENaC in CF airways (Caldwell et al., 2005).
Whilst proteolysis of ENaC has been well described (Hughey et al., 2007; Rossier and
Stutts, 2008), little is known regarding how proteolysis ENaC is regulated by airway
epithelia. However, we recently identified SPLUNC1 as a potent inhibitor of ENaC that is
secreted into the ASL where it binds extracellularly to ENaC and prevents it from being
proteolytically cleaved/activated (Garcia-Caballero et al., 2009; Garland et al., 2013; Hobbs
et al., 2013). We have yet to perform single channel analysis of ENaC ± SPLUNC1.
However, our data suggest that SPLUNC1 most likely reduces the number of ENaCs in the
plasma membrane (Rollins et al., 2010). Furthermore, while we cannot yet rule out
additional effects of SPLUNC1 on the open probability of ENaC, the slow onset of
inhibition (~45 min in human bronchial airway epithelial cultures; HBECs) is more
consistent with an effect on channel number than channel gating (Hobbs et al., 2013).
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3. The mucus clearance component of the lung’s innate defense system
It has been estimated that the number of airborne bacteria may vary as dramatically as ~200
bacteria/m3 of air in an office building to ~700,000 bacteria/m3 of air in a slaughter house
(Andersen, 1977). Despite these variations, by the time air reaches the alveolar region of a
healthy lung it has been sterilized and humidified. The ASL lining the conducting airways
helps ensure this by continuously moving up the airways, either by ciliary beating and/or
cough clearance, until being swallowed or expectorated. As such, ASL is the first point of
contact with inhaled pathogens. ASL is approximately isotonic with plasma (Knowles et al.,
1997) and contains over 100 proteins including proteases and their inhibitors, mucins, and
anti-microbial peptides, such as lysosome and SPLUNC1 (Kesimer et al., 2009; Casado et
al., 2005). ASL consists of a ~7 µm periciliarly liquid layer with an overlying mucus layer.
The periciliarly liquid layer bathes the cilia and acts as a lubricant that facilitates mucus
clearance. Mucus is a non-Newtonian fluid whose physical properties are largely determined
by the presence of gel-forming mucins such as MUC5AC and MUC5B (Fahy and Dickey,
2010). Mucus hydration has a large effect on its ability to be cleared by the underlying
epithelia (Button et al., 2012; Tarran et al., 2001a). Thus, the better hydrated the ASL; the
better mucus can be cleared. This is illustrated by the genetic disease
pseudohypoaldosteronism (PHA), where ENaC activity is severely diminished. In these
patients, the lungs are very well hydrated due to the lack of ENaC-led Na+/ASL absorption;
consequently, mucus clearance rates are much greater than those seen in normal airways
(Kerem et al., 1999).
4. SPLUNC1 and airway surface liquid hydration
We have previously shown that normal HBECs can autoregulate ion transport and ASL
height in order to preserve mucus transport rates (Matsui et al., 1998; Tarran et al., 2001a,
2001b). In large part, this homeostasis is mediated by SPLUNC1, which acts as an
autocrine, negative regulator of ENaC (Garcia-Caballero et al., 2009). For example, when
SPLUNC1 was stably knocked down by shRNA, normal HBECs failed to regulate ENaC
activity leading to ASL dehydration (Garcia-Caballero et al., 2009). When recombinant
SPLUNC1 was added to the ASL, ENaC inhibition and ASL homeostasis were restored,
suggesting that extracellular SPLUNC1 is sufficient to regulate ENaC (Garcia-Caballero et
al., 2009). Interestingly, this function of SPLUNC1 is not exclusive to the lung: ENaC also
regulates Na+ absorption and mucus hydration/clearance in the auditory canal (Kim and
Marcus, 2011); and knockdown of SPLUNC1 in the chinchilla inner ear causes a failure of
mucus clearance in this organ (McGillivary and Bakaletz, 2010), which is consistent with a
lack of SPLUNC1 causing ENaC hyperactivity.
SPLUNC1 is not a rapid inhibitor of ENaC and takes about 45 min to take full effect
(Garcia-Caballero et al., 2009). Mucus clearance normally occurs at a rate of 10 mm/min
(Feng et al., 1999), therefore, it is unlikely that SPLUNC1 exerts minute-to minute changes
in mucus clearance rates via ENaC. However, SPLUNC1 may also indirectly regulate
chloride/ASL secretion by modulating the apical membrane potential: Since the ASL
chloride concentration is approximately fourfold greater than the intracellular chloride
concentration, there is no chemical gradient for chloride secretion (Boucher, 1994).
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However, inhibition of ENaC hyperpolarizes the apical membrane and provides an electrical
driving force for chloride secretion (Boucher, 1994). Consistent with these observations, we
have shown that the degree of ENaC activity greatly influences the ability of HBECs to
secrete chloride and ASL (Tarran et al., 2006). That is, when ENaC is inhibited, the cystic
fibrosis conductance regulator (CFTR) chloride channel can induce chloride/ASL secretion;
and when ENaC is active, the apical plasma membrane is depolarized and there is no
electrical gradient for CFTR-mediated Cl−/ASL secretion. We therefore propose that
SPLUNC1 sets the level of ENaC activity, which in addition to regulating absorption rates,
also determines how effective chloride will be at driving ASL secretion. Of note, when
ENaC is inhibited, the onset of chloride/ASL secretion is very rapid and can occur within 60
s, which may allow for fine-tuning of ASL volume (Tarran et al., 2001b).
5. SPLUNC1 and CF lung disease
The lungs of patients with CF are typified by the accumulation of dehydrated, viscous
mucus on airway surfaces, leading to bronchiolar occlusion and bacterial infection (Chmiel
and Davis, 2003; Gibson et al., 2003). However, the primary genetic defect in CF is
dysfunction of the CFTR chloride channel (Welsh and Smith, 1993), and a long-term
challenge has been to reconcile knowledge of this genetic defect with clinical observations
from affected lungs (e.g., sodium hyperabsorption, mucus accumulation, chronic
inflammation, neutrophilia, and bronchiectasis). It has been proposed that the CFTR is itself
a negative regulator of ENaC and that the initiating event in CF lung disease is depletion of
the ASL due to chloride hyposecretion and sodium hyperabsorption, the combination of
which causes dehydrated mucus to adhere to airway surfaces, preventing mucus clearance
(Knowles and Boucher, 2002). This lack of clearance allows concentrated mucus plaques to
accumulate until the airways become occluded and are colonized by bacteria. Following
bacterial colonization, macrophages and neutrophils attempt to infiltrate the mucus plaques
and attack the bacteria, but are excluded as a consequence of the increased mucus viscosity.
Despite being unable to reach the bacteria, these immune cells still release their contents,
including neutrophil elastase, causing a vicious cycle of infection, inflammation, and tissue
damage (Chmiel and Davis, 2003; Gibson et al., 2003; Worlitzsch et al., 2002). ENaC
hyperactivity contributes to the dehydration of ASL volume by removing both Na+ ions and
water molecules. This in turn may contribute to mucus stasis and an increased incidence of
airway infections that frequently lead to patient death. Similar lung disease has been
demonstrated in vivo in a transgenic murine model overexpressing ENaC, thus linking
sodium hyperabsorption, volume depletion, and inflammation (Mall et al., 2004).
Whilst the mechanism underlying sodium hyperabsorption in CF airways is not fully
understood, CF ENaC is abnormally hyperactive due in part to its excessive proteolytic
cleavage, indicating that CF ENaC may be in a more active state (Boucher et al., 1986;
Gentzsch et al., 2010). Curiously, this increase in ENaC activity takes place in the face of
elevated SPLUNC1 expression, which suggests that SPLUNC1 is non-functional in CF
airways (Roxo-Rosa et al., 2006; Bingle et al., 2007). SPLUNC1 can be detected in CF
HBECs (Garland et al., 2013). However, these cultures fail to autoregulate ASL height,
suggesting that SPLUNC1 is non-functional in CF airways (Matsui et al., 1998). Because
SPLUNC1-ENaC interactions are extracellular, and because CF ENaC is still responsive to
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protease inhibitors such as aprotinin (Donaldson et al., 2002; Tarran et al., 2006), we
hypothesize that the altered CF ASL microenvironment prevents interactions between ENaC
and SPLUNC1. Indeed, CF ASL has a lower pH than normal ASL due to the lack of
bicarbonate secretion through CFTR (Coakley et al., 2003; Cho et al., 2011; Garland et al.,
2013; Poulsen et al., 1994). Further analysis revealed that SPLUNC1’s ability to bind to
ENaC-expressing epithelia, and its ability to inhibit ENaC was strongly pH-dependent over
the physiological range (i.e., pH 6.0–7.0) and were inhibited by acid pH (Garland et al.,
2013). Thus, the failure of SPLUNC1 to bind and inhibit CF ENaC was not due to the lack
of CFTR per se, but rather to the failure of CFTR to regulate ASL pH to appropriate levels.
We found that increasing CF ASL pH toward normal levels restored SPLUNC1 function
(i.e., CF ENaC was inactivated) and CF ASL hydration levels were increased (Garland et al.,
2013). Thus, we propose that CFTR indirectly regulates SPLUNC1–ENaC interactions via
its secretion of bicarbonate and the subsequent buffering of ASL pH into the neutral range
favors SPLUNC1 binding.
6. Structure of SPLUNC1
We have recently resolved the crystal structure of human SPLUNC1 to 2.8 Å resolution, and
refined the structure to a final model that included residues 43–254 of the 256 amino acid
protein (Garland et al., 2013) (Fig. 1). SPLUNC1 shares structural homology with the N-
terminal half of the larger, human bacterial permeability increasing (BPI) protein (Beamer et
al., 1997). The region in BPI where lipopolysaccharide (LPS) binds, a central cavity within
this protective protein, is gated/occluded in SPLUNC1 by a C-terminal helix (α6) that is
unique to SPLUNC1 and not seen in BPI (Fig. 1B). Still, the hydrophobic nature of the
residues surrounding the internal, LPS-binding cavity of BPI is largely retained in
SPLUNC1, suggesting that with the correct conformational change SPLUNC1 could bind to
a large hydrophobic ligand like LPS. Despite these similarities, SPLUNC1 is clearly a
unique molecule. Not only is it half the size of BPI, but it also possesses unique structural
elements. For example, SPLUNC1 contains a leader peptide, residues 1–19 (not retained in
the construct used for crystallization), followed by an 18 residue domain (G22-A39) we
termed the “S18 region” that is not present in BPI or other BPI-type proteins (Garland et al.,
2013). An 18 amino acid peptide based on this sequence failed to show any structure by
circular dichroism (Hobbs et al., 2013); and unfortunately, despite the fact that this region
was present in the 20–256 residue construct used for crystallization, this region was
disordered in the resolved structure and could not be visualized within the electron density
maps (Garland et al., 2013). This was one of two loop regions not observed in this 2.8 Å
resolution structure, the other being an 11-residue stretch comprised of amino acids 78–88
(Fig. 1B).
7. Structural insights into SPLUNC1’s pH-dependency
In contrast to SPLUNC1, which fails to function in CF HBECs (Garland et al., 2013), a
peptide corresponding to SPLUNC1’s ENaC inhibitory domain/S18 region (Fig. 1A)
inhibited ENaC-led ASL volume depletion equally well in both normal and CF HBECs
(Hobbs et al., 2013). Further experiments revealed that this S18 peptide was pH-independent
and that only the complete SPLUNC1 molecule is pH-dependent (Garland et al., 2013). The
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resolved structure of SPLUNC1 (the first of this factor family from the mammalian lung)
provided key information regarding the ability of intact SPLUNC1 to regulate the activity of
ENaC in a pH-dependent manner. We identified a patch of electrostatic residues on the
surface of SPLUNC1, including Asp-112, Lys-138, Arg152, and Asp-193 that, when
disrupted by targeted mutations to alter their ionic character, significantly impacted
SPLUNC1’s ability to bind ENaC and regulate ASL height (Garland et al., 2013). For
example, the mutation of either Arg-152-Glu or Asp-193-Asn eliminated the pH-dependent
regulation of ENaC by SPLUNC1, causing SPLUNC1 to inhibit ENaC equally well
regardless of pH and restored the ability of ENaC to regulate ASL homeostasis in CF
HBECs. Importantly, when the electrostatic character of these two residues are returned, but
their positions swapped as in a Arg-152-Asp/Asp-193-Arg double mutation, SPLUNC1
returns to functioning normally as a pH-dependent binder and regulator of ENaC (Garland et
al., 2013). These results support the conclusion that the electrostatic surface character of
SPLUNC1 plays an important role in ENaC/ASL height homeostasis. Indeed, of the 35
surface-exposed electrostatic residues on human SPLUNC1, more than three-quarters are
conserved in SPLUNC1’s known sequence, including its five histidines (Fig. 2A and B).
Typically, electrostatic amino acids like Asp, Glu, Lys, Arg, and His found on protein
surfaces demonstrate less conservation of identity, as they only assist in the general
solubility of globular proteins. Thus, the conservation of these residues in SPLUNC1 is
notable and suggests that evolutionary pressure is in place to maintain them, perhaps by
assisting in the proper pH-dependent regulation of ENaC.
8. Strategies for restoring proper ENaC regulation in CF airways
Taken together, our data suggest that it may be possible to restore proper ENaC regulation
and lung hydration by either increasing CF ASL pH (and thus restoring native SPLUNC1
function) or by adding a peptide of SPLUNC1’s ENaC inhibitory domain. However, since
SPLUNC1 is degraded by neutrophil elastase a highly abundant protease in CF sputum, CF
SPLUNC1 may be degraded and nonfunctional (Jiang et al., 2013; Delacourt et al., 2002;
Konstan et al., 1994). If this is the case, then raising ASL pH may not restore SPLUNC1
function in CF airways, suggesting that the addition of a recombinant peptide may be a more
favorable treatment option. To the best of our knowledge, the degree of degradation of
SPLUNC1 protein has not been ascertained in sputum from CF patients. However, peptides
corresponding to the G22-A39 region were detectable in sputum from normal but not CF
subjects (Hobbs et al., 2013), suggesting that abnormal SPLUNC1 degradation occurs in CF
lungs. Clearly, more experiments will be required to evaluate SPLUNC1 function in CF
patients, especially now that we know that fragments of SPLUNC1 may retain biological
activity when removed from the SPLUNC1 protein (Hobbs et al., 2013).
9. Model of pH dependent SPLUNC1 function
Together, our functional and structural data support a model wherein SPLUNC1 serves to
plug the operational ENaC “drain” that removes sodium ions and water from the ASL
overlying airway epithelia (Fig. 3). At normal pH in healthy lungs (NL), SPLUNC1 can
effectively contact ENaC and prevent the proteolytic activation of this channel. The proper
ASL height allows cilia to function, and to beat appropriately to move mucous and bacterial
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pathogens away from the epithelia surface. Importantly, the pH is decreased relative to
healthy ASL and it would appear that pH alone is sufficient to disrupt SPLUNC1’s contact
with ENaC, allowing ENaC to remove Na+ ions and water, leading to ASL dehydration and
trapped cilia that are unable to mobilize either mucous or pathogenic cells (Garland et al.,
2013) (Fig. 3). This hypothesis is supported by our data demonstrating that elevation of CF
ASL pH prevents cleavage of ENaC and restores ASL volume homeostasis (Garland et al.,
2013). Importantly, the pH sensitivity of ENaC is lost when SPLUNC1 is stably knocked
down by shRNA (Garland et al., 2013). We have found that the adjustment of ASL pH does
not improve the ability of the S18 peptide to regulate ENaC, indicating that the complete
SPLUNC1 molecule appears essential in pH-dependent ENaC control.
10. Conclusions
As we mentioned at the start of this review, SPLUNC1 is a multifunctional protein that
impacts several aspects of innate defense of the lung, which we are only beginning to
understand. Looking beyond ENaC regulation, it will be interesting to see whether the
crystal structure of SPLUNC1 will help determine the molecular basis for its other
functions.
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SPLUNC1 amino acid sequence and crystal structure. (A) The cleaved leader sequence is
highlighted gray. The ENaC inhibitory domain (a.k.a. the S18 region) is highlighted in
yellow. Basic (blue) and acidic (red) residues known to confer pH-sensitivity on SPLUNC1
are shown in bold. The underlined pair of residues constitute one potential salt bridge while
the second set of residues constitute a second salt bridge. (B) Ribbon diagram of the crystal
structure of human SPLUNC1.
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Conserved electrostatic residues on the surface of SPLUNC1. (A) Conserved electrostatic
residues on SPLUNC1 as shown in panel A. (B) Conserved electrostatic residues on the
opposite side of SPLUNC1 as indicated. Acidic residues are shown in red while basic
residues are shown in blue. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of the article.)
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Schematic of airway surface liquid (transparent blue or red) above ciliated epithelial cells as
depicted for normal lung (NL, left) and cystic fibrosis (CF, right) lung. The heterotrimeric
epithelial sodium channel (ENaC) is rendered in orange, soluble SPLUNC1 in blue, and
sodium ions as yellow. In normal (NL) airways, SPLUNC1 binds to and regulates ENaC,
keeping a healthy level of sodium and water that allows cilia to function. In CF, low fluid
pH prevents SPLUNC1’s regulation of ENaC, allowing isotonic removal of sodium and
water by this channel, dehydrating the ASL and significantly reducing cilia function. (For
interpretation of the references to color in this figure legend, the reader is referred to the web
version of the article.)
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